Irked by a pharma CEO's broken promise? We're making a list

FiercePharma is compiling a list of the biggest broken promises by pharma executives in recent years. (Shutterstock/Deviney Designs)

Biotech and pharma CEOs are used to having their words recorded. Whether it's at an investor conference, an industry confab, a press conference or a quarterly earnings call, CEO statements end up everywhere from webcasts to reporters' notebooks.

Sometimes, those statements aren't just facts. They're pledges of one kind or another. And while executives often hold true to their public statements, sometimes they just don't.

This fall, we’re planning to highlight the biggest promises made and broken by biopharma execs in recent years—and we’re turning to readers to help compile the list. 

Be it a promise not to raise prices or settle a lawsuit, a promise to hit a particular long-term sales target, a promise not to sell a company, unforeseen layoffs, misleading M&A comments or more, we want to hear your ideas for the upcoming feature. Anytime a pharma CEO said one thing and did another, that’s worth noting. 

We’ll plan to highlight a group of the broken promises in a special report this October. Please share your ideas in this form. Nominations are open until Aug. 30. Questions in the meantime? Feel free to get in touch through email or Twitter.

Read more on

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

Moderna will delegate fill-finish duties for "hundreds of millions" of doses of its COVID-19 vaccine to Spain's Laboratorios Farmacéuticos Rovi.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.